Gemdale USA has refinanced Aperture Del Mar, a newly opened 538,000-square-foot life sciences campus in San Diego, with $90 million in mezzanine debt from Tishman Speyer and Breakthrough Properties, the latter a joint venture between Tishman Speyer and Bellco Capital.
The refinancing signals continued investor appetite for life sciences real estate despite recent market headwinds. Aperture Del Mar represents Class A space designed for biotech, pharmaceutical, and research tenants in one of the country's top life sciences hubs. The property's quick refinance after opening suggests strong leasing velocity or pre-leasing commitments that give lenders confidence in cash flow stability.
Mezzanine debt sits between senior mortgages and equity in the capital stack, offering Gemdale more leverage while giving Tishman Speyer and Breakthrough Properties a higher return profile than traditional senior loans. The structure works well for recently stabilized assets with predictable tenant rosters, a characteristic Aperture likely demonstrates given its fresh opening.
For Gemdale USA, the refinance unlocks capital to deploy elsewhere while maintaining control of the operating asset. The property benefits from San Diego's reputation as a life sciences anchor, home to major research institutions and established biotech clusters. This geography directly impacts tenant demand and lease rates.
Tishman Speyer's involvement underscores the real estate giant's strategic pivot into life sciences. By partnering with Bellco Capital through Breakthrough Properties, Tishman Speyer gains specialized expertise in lab and clinical space while diversifying beyond traditional office and mixed-use development. Life sciences properties trade on different fundamentals than standard commercial real estate. Tenants sign longer leases, accept higher rents for specialized infrastructure, and remain less sensitive to economic cycles.
For institutional investors watching the life